Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
TERN 11.06.2024
About Gravity Analytica
FOSTER CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in November.
UBS Global Healthcare ConferenceFormat: Fireside ChatDate and Time: Wednesday, November 13, 2024 at 8:45 a.m. PTLocation: Terranea Resort, Rancho Palos Verdes
Jefferies London Healthcare ConferenceFormat: Fireside ChatDate and Time: Tuesday, November 19, 2024 at 5:00 p.m. GMTLocation: Waldorf Hilton, London
Live webcasts of the fireside chats will be available on the investor relations page of the Terns Pharmaceuticals website athttp://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.
About Terns PharmaceuticalsTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate.
Contacts for Terns
InvestorsJustin Nginvestors@ternspharma.com
MediaJenna UrbanBerry & Company Public Relationsmedia@ternspharma.com
